AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9121974
Drug: Transvenous lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvenous lead linked to a patch electrode
Trial: 3552909
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MPSS) 1-2 g
Trial: 28906574
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of picosecond laser (1 064 and 595 nm) and 2% hydroquinone (HQ) cream for 7 weeks and 5 weeks of laser treatment (weekly).
Trial: 28906574
Drug: 2% hydroquinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% hydroquinone (HQ) cream alone for 7 weeks.
Trial: 28906574
Drug: Picosecond laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picosecond laser treatment side at week 7.
Trial: 25920470
Drug: Neurophysiological-based conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurophysiological-based conventional therapy
Trial: 21742943
Drug: Algae‐derived DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algae‐derived DHA (12 g·ewe(‐1)·d(‐1))
Trial: 20003384
Drug: Intensive sexological
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive sexological treatment
Trial: 20003384
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (waiting list)
Trial: 17100679
Drug: AV sequential
RxNorm normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV sequential pacing mode
Trial: 9329422
Drug: Topical iodine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical iodine-containing antiseptics (n = 73)
Trial: 9329422
Drug: Topical iodine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical iodine-containing antiseptics (n = 24)
Trial: 8204876
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin‐1 beta (rhIL‐1 beta) at 0.01, 0.02, 0.05 microgram/kg administered by intravenous infusion once a day for 5 doses.
Trial: 28858553
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal Bupivacaine (LB) 133 mg/10 mL
Trial: 25908603
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus bevacizumab 5 mg/kg
Trial: 25908603
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus bevacizumab 10 mg/kg
Trial: 18504478
Drug: Intranasal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (INS)
Trial: 27756405
Drug: Active binocular
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active binocular treatment (videogame-based) for 6 weeks
Trial: 27756405
Drug: Active binocular
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active binocular treatment (videogame-based)
Trial: 7753966
Drug: Ipsapirone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone 5 mg administered by mouth three times daily for 14 days
Trial: 7753966
Drug: Ipsapirone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone 5 mg
Trial: 2113488
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment cycles pooled
Trial: 2113488
Drug: Adjunctive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapy with LA
Trial: 2113488
Drug: Serum concentrations
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum concentrations of luteal phase steroids
Trial: 365537
Drug: S-carboxy-methyl-cysteine (S.C.M.C.)
RxNorm normalized name: S-methyl methanethiosulfonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-carboxy-methyl-cysteine (S.C.M.C.) 3 g/24h
Trial: 29463627
Drug: Spironolactone (12.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5-50 mg QD)
Trial: 29463627
Drug: Clonidine (0.1-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1-0.3 mg BID)
Trial: 28078857
Drug: Sevoflurane (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane (1% administered immediately after the beginning of cardiopulmonary bypass until the end of treatment)
Trial: 17928750
Drug: Duodenoscopic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duodenoscopic infusion of 90 mL of sodium phosphate (NaP) diluted with 180 mL of water (group EA)
Trial: 17928750
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered 45 mL of sodium phosphate (NaP) (group OA)
Trial: 10915398
Drug: two 160-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 160-mg capsules once daily (OD)
Trial: 10915398
Drug: one 160-mg
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 160-mg capsule twice daily (BID)
Trial: 8605792
Drug: Lorazepam (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (intermittent intravenous injection, 1.6 +/- 0.1 mg/8 hrs)
Trial: 8605792
Drug: Midazolam (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (continuous intravenous infusion, 14.4 +/- 1.2 mg/8 hrs)
Trial: 17552048
Drug: Infliximab plus
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab plus MTX (3 mg/kg)
Trial: 17552048
Drug: Infliximab plus
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab plus MTX (6 mg/kg)
Trial: 17552048
Drug: Infliximab plus
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab plus MTX (3 mg/kg) and (6 mg/kg)
Trial: 9611008
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with a combination of cis‐diamminedichloroplatinum (CDDP), vincristine, mitomycin C, and peplomycin (POMP)
Trial: 1823658
Drug: Dental fear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental fear treatment
Trial: 28697226
Drug: Topical proprietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical proprietary procedural enhancement system (PES) containing a combination of active ingredients including a tripeptide and hexapeptide (TriHex Technology™)
Trial: 21259031
Drug: Intravenous amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amoxicillin and clavulanic acid (single dose)
Trial: 21259031
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo (equal volume, intravenous bolus)
Trial: 11549680
Drug: Glucagon-like peptide-1
RxNorm normalized name: Glucagon-like peptide-1 (GLP-1) analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon-like peptide-1 (7-36) amide infusion
Trial: 23243254
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (10 mg•kg(‐1) of feed; VE‐10)
Trial: 23243254
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (100 mg•kg(‐1) of feed; VE‐100)
Trial: 23243254
Drug: Oregano essential
RxNorm normalized name: Oregano
DrugBank: Oregano (DB10677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oregano essential oil (100 mg•kg(‐1) of feed; OR‐100)
Trial: 11289700
Drug: Propylthiouracil (PTU)
RxNorm normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylthiouracil (PTU) 3 x 100 mg/d for 30 d
Trial: 3607818
Drug: Pyrethrin-piperonyl-butoxide lotion
RxNorm normalized name: piperonyl butoxide / pyrethrins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrethrin-piperonyl-butoxide lotion
Trial: 29289531
Drug: GSR biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSR biofeedback therapy
Trial: 26551986
Drug: Statin arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin arm (atorvastatin 80 mg/10 mg or simvastatin 20 mg)
Trial: 16618298
Drug: Fresh autologous
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh autologous whole blood (15 ml x kg(‐1) collected prior to heparinization)
Trial: 16618298
Drug: 5% albumin
RxNorm normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin (15 ml x kg(‐1) infused intravenously)
Trial: 4016054
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyaluronate plus systemic acetazolamide
Trial: 29143484
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg d‐1 folate after 4 weeks
Trial: 29143484
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg d‐1 folate after 4 weeks
Trial: 29143484
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg d‐1 folate after 8 weeks
Trial: 29143484
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg d‐1 folate after 8 weeks
Trial: 25354015
Drug: Daily online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily online tube potential‐cone beam CT (CBCT) image guidance with reduced CTV2 to PTV2 margins (3 mm)
Trial: 17880774
Drug: Thiamphenicol glycinate
RxNorm normalized name: thiamphenicol glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol glycinate acetylcisteinate (TGA) 500 mg b.i.d. intramuscularly on the first day and TGA 500 mg b.i.d. by aerosol during the following days (n=151)
Trial: 17880774
Drug: Thiamphenicol glycinate
RxNorm normalized name: thiamphenicol glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol glycinate acetylcisteinate (TGA) 250 mg b.i.d. by aerosol (n=149)
Trial: 17880774
Drug: Other standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other standard antibiotics given intramuscularly (n=268)
Trial: 17880774
Drug: Other standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other standard antibiotics given orally (n=249)
Trial: 16627794
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril for all, plus indapamide for some)
Trial: 14596362
Drug: Candesartan 8/16mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8/16mg and Hydrochlorothiazide 12.5 mg (combination)
Trial: 8612863
Drug: IV infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions of albumin (n = 13)
Trial: 8612863
Drug: IV infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions of albumin
Trial: 1295286
Drug: Pinaverium bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide (50 mg, two tablets)
Trial: 6540581
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg orally)
Trial: 19950090
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg orally for the first four days
Trial: 19950090
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg orally from the fifth to the eighth day
Trial: 11251731
Drug: Reiki Touch
RxNorm normalized name: benzethonium chloride Medicated Liquid Soap [Lysol Healthy Touch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reiki Touch therapy
Trial: 9444543
Drug: Fluoxetine (8-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (8-week treatment)
Trial: 25619549
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of an oral loop diuretic at discharge
Trial: 25619549
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in loop diuretic dose at discharge for patients already established on diuretics prior to admission
Trial: 16446318
Drug: High-dose alkylating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alkylating chemotherapy (cyclophosphamide, thiotepa and carboplatin)
Trial: 16446318
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (FEC followed by radiation therapy and tamoxifen)
Trial: 12582945
Drug: Pseudoephedrine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine (60 mg four times daily)
Trial: 12582945
Drug: Phenylpropanolamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (25 mg four times daily)
Trial: 11432680
Drug: Ceftriaxone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (single preoperative dose)
Trial: 8415806
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (4 g), sardine oil (2.4 g), vitamin E (200 mg) for 4 weeks
Trial: 8415806
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil and fish oil treatment
Trial: 2877480
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for hypertension
Trial: 28282796
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level continuous heat with Ibuprofen (LLCH + IP)
Trial: 28282796
Drug: Sham LLCH
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham LLCH with sham Ibuprofen
Trial: 25075645
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream 1
Trial: 25075645
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream 2
Trial: 21610557
Drug: Low-volume ultrasound-guided
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume ultrasound-guided ankle block (16 mL ropivacaine 0.5%)
Trial: 21610557
Drug: Conventional-volume surface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-volume surface landmark technique (30 mL ropivacaine 0.5%)
Trial: 12803865
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) alone (30 mg/kg base given over 3 days)
Trial: 12803865
Drug: Chloroquine plus
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine plus ketotifen (CQK) (0.25 mg at presentation followed by 0.125 mg/kg every 8 h for 5 days)
Trial: 8851579
Drug: 20% fat
RxNorm normalized name: Intralipid 20% Fat Emulsion for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% fat emulsion formulation (Intralipid; 20% IL)
Trial: 8851579
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose (glucose) (5% D) solution
Trial: 6720619
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement (1 g/day for 8 days)
Trial: 30267357
Drug: Local glucocorticoid
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local glucocorticoid (GC) injection combined with local anaesthetic
Trial: 28082816
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus NCFM (low-dose)
Trial: 28082816
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus NCFM (high-dose)
Trial: 11867886
Drug: Vitamin supplements
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplements (folic acid 2 mg, B(6) 25 mg, B(12) 500 mug)
Trial: 11210402
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (2.4 g)
Trial: 18430053
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day) for 4 months
Trial: 18430053
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg/day) for 4 months
Trial: 16670247
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg memantine twice a day
Trial: 15030296
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ACE inhibitors or angiotensin II receptor antagonists and diuretics
Trial: 15030296
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors or angiotensin II receptor antagonists alone
Trial: 10663453
Drug: Lariam (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lariam (reference formulation)
Trial: 1586398
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements (calcium, magnesium, potassium, fish oil)
Trial: 22187126
Drug: Dose-dense sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense sequential epirubicin 110 mg/m(2) and paclitaxel 250 mg/m(2)
Trial: 26164674
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg naltrexone
Trial: 17394081
Drug: Calcium polycarbophil
RxNorm normalized name: Calcium Polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium polycarbophil (3 g/day) plus bifidobacterium (3 g/day)
Trial: 17394081
Drug: Bifidobacterium (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium (3 g/day)
Trial: 12087454
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of CMF for patients at least 40 years old with oestrogen-receptor-positive tumours
Trial: 12087454
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of CMF for women with oestrogen-receptor-negative tumours
Trial: 10215752
Drug: Subcutaneous lenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lenograstim (0.5, 2, 5, or 10 microg kg(‐1))
Trial: 10215752
Drug: Intravenous lenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lenograstim (0.5, 2, 5, or 10 microg kg(‐1))
Trial: 10215752
Drug: Subcutaneous lenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lenograstim (5 microg kg(‐1))
Trial: 10215752
Drug: Intravenous lenograstim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lenograstim (5 microg kg(‐1))
Trial: 2170718
Drug: 1.0 microgram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 microgram dose group
Trial: 2170718
Drug: 0.5 microgram
RxNorm normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 microgram dose group
Trial: 2170718
Drug: 0.25 microgram
RxNorm normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 microgram dose group
Trial: 374162
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ventolin tablets and Phyllocontin tablets
Trial: 374162
Drug: Ventolin tablets
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin tablets
Trial: 9240864
Drug: Wide access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Wide access to drugs
Trial: 3473681
Drug: Consolidation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation therapy (COAP or MAZE)
Trial: 3473681
Drug: Conventional doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional doses of ara‐C
Trial: 23344474
Drug: Frequent daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent daily hemodialysis
Trial: 22333201
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/d) for 12 weeks
Trial: 9802618
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen therapy with no irradiation